The ACR/CHEST ILD Guidelines in Practice: Register Now for This Informative Webinar

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Articles by Natasha Yetman

After COVID-19-Associated MIS-C, Immune Changes Resolve

Marilynn Larkin  |  

NEW YORK (Reuters Health)—A new study of multisystem inflammatory syndrome in children (MIS-C) shows that the immune system is profoundly altered during acute illness, but gradually returns back to normal. MIS-C is distinct from both COVID-19 and Kawasaki disease, but is associated with previous SARS-CoV-2 infection, the immunological profiling study reveals. Dr. Manu Shankar-Hari, an…

Bisphosphonates Reduce Bone Toughness Over Time

Will Boggs, MD  |  

NEW YORK (Reuters Health)—Using bisphosphonates for several years is associated with increasing brittleness and decreasing toughness of bone, according to a new review. “Long-term treatment with bisphosphonates can have negative side effects in some people because of their effects on bone toughness [toughness = the energy that bone tissue can absorb before cracking],” David B….

NIH Taps Lindsey Criswell, MD, MPH, DSc, as Director of NIAMS

National Institutes of Health  |  

National Institutes of Health Director Francis S. Collins, MD, PhD, has selected Lindsey A. Criswell, MD, MPH, DSc, as director of NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). A rheumatologist, Dr. Criswell is currently the vice chancellor of research at the University of California, San Francisco (UCSF). She is a professor…

Submit a Nomination for the 2021 Lurie Prize in Biomedical Sciences

  |  

Each year, the Foundation for the National Institutes of Health (FNIH) recognizes outstanding achievements by a promising young scientist in biomedical research by bestowing the Lurie Prize in Biomedical Sciences. First presented in 2013, this $100,000 award is made possible by a gift from philanthropist Ann Lurie. Nominations for the 2021 Lurie Prize in Biomedical…

U.S. Hip Fracture Incidence Declines with Reductions in Smoking & Drinking

Lisa Rapaport  |  

(Reuters Health)—Age-adjusted hip fracture incidence has declined in the U.S. over the past four decades, aided by a decline in smoking and alcohol consumption, a new study suggests. Researchers examined data on 4,918 men and 5,634 women who participated in the prospective Framingham Heart Study from 1970 to 2010. Overall, the age-adjusted incidence of hip…

Telemedicine Highlights Health Disparities During Pandemic

Carolyn Crist  |  

NEW YORK (Reuters Health)—The COVID-19 pandemic has accelerated the expansion of telemedicine across the U.S., which has opened up access to doctor’s offices for families with limited resources. But at the same time, the health disparity gap could continue to widen unless safeguards are put into place, according to a pair of new editorials. “There…

IL-1-Beta Blockade May Slow OA Progression

Reuters Staff  |  

NEW YORK (Reuters Health)—Interleukin (IL) 1 beta is a key player in the osteoarthritis (OA) inflammatory process and inhibiting it may help slow the disease process, according to an exploratory analysis of data from the CANTOS trial.1 CANTOS participants who were treated with the IL-1-beta inhibitor canakinumab had a significantly lower rate of total hip…

Tocilizumab Fails Late-Stage Trial for COVID-19

John Revill  |  

ZURICH (Reuters)—Roche’s attempt to retool its rheumatoid arthritis drug Actemra/RoActemra (tocilizumab) to treat patients hospitalized with severe COVID-19-related pneumonia has failed in a late-stage trial, the Swiss company said on July 29. Roche launched the 452-patient trial in March as it joined other pharmaceutical companies seeking to re-purpose existing medicines to fight the pandemic. The…

Denosumab Dosing Delays Tied to Increased Fracture Risk

Megan Brooks  |  

NEW YORK (Reuters Health)—Denosumab injection delays of more than four months are associated with an increased risk of fracture compared with on-time injections, especially at the spine, new research indicates. “This study suggests the importance of timely denosumab administration when used for long-term osteoporosis management,” the researchers write in Annals of Internal Medicine.1 “When starting…